Zacks: Brokerages Expect Minerva Neurosciences Inc (NASDAQ:NERV) Will Announce Earnings of -$0.41 Per Share

Analysts expect Minerva Neurosciences Inc (NASDAQ:NERV) to post earnings per share of ($0.41) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Minerva Neurosciences’ earnings. The highest EPS estimate is ($0.36) and the lowest is ($0.49). Minerva Neurosciences reported earnings per share of ($0.34) during the same quarter last year, which would indicate a negative year over year growth rate of 20.6%. The company is expected to announce its next earnings report on Tuesday, March 10th.

According to Zacks, analysts expect that Minerva Neurosciences will report full-year earnings of ($1.48) per share for the current financial year, with EPS estimates ranging from ($1.58) to ($1.44). For the next fiscal year, analysts anticipate that the company will report earnings of ($1.69) per share, with EPS estimates ranging from ($3.32) to ($0.91). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that cover Minerva Neurosciences.

Minerva Neurosciences (NASDAQ:NERV) last issued its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.01.

A number of brokerages have recently issued reports on NERV. BidaskClub raised shares of Minerva Neurosciences from a “strong sell” rating to a “sell” rating in a research report on Friday, August 23rd. Chardan Capital reaffirmed a “buy” rating on shares of Minerva Neurosciences in a research report on Monday, December 2nd. William Blair assumed coverage on shares of Minerva Neurosciences in a research note on Wednesday, September 18th. They issued an “outperform” rating and a $26.00 price objective for the company. Zacks Investment Research downgraded shares of Minerva Neurosciences from a “buy” rating to a “hold” rating in a report on Tuesday, October 29th. Finally, ValuEngine lowered shares of Minerva Neurosciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, September 30th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. Minerva Neurosciences has a consensus rating of “Buy” and a consensus target price of $17.44.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Minerva Neurosciences during the 3rd quarter valued at $35,000. Public Employees Retirement System of Ohio bought a new position in shares of Minerva Neurosciences in the second quarter worth $54,000. Parametric Portfolio Associates LLC bought a new position in shares of Minerva Neurosciences in the second quarter worth $56,000. Quantitative Systematic Strategies LLC bought a new position in shares of Minerva Neurosciences in the second quarter worth $62,000. Finally, Jane Street Group LLC acquired a new position in Minerva Neurosciences in the second quarter valued at about $88,000. 78.94% of the stock is owned by hedge funds and other institutional investors.

Shares of NERV traded up $0.11 during midday trading on Friday, reaching $6.25. 289,495 shares of the stock were exchanged, compared to its average volume of 313,383. Minerva Neurosciences has a twelve month low of $4.01 and a twelve month high of $8.83. The company has a market cap of $239.62 million, a P/E ratio of -4.84 and a beta of 1.59. The stock’s 50 day simple moving average is $5.16 and its 200 day simple moving average is $5.97.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.

Recommended Story: Producer Price Index (PPI)

Get a free copy of the Zacks research report on Minerva Neurosciences (NERV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Minerva Neurosciences (NASDAQ:NERV)

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.